Korro Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Korro Bio, Inc. (KRRO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $2.17 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2023-11-02
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-09-30 was $2.17M, a 29.97% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-06-30 was $2.32M, a 35.86% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-03-31 was $2.87M, a 43.61% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-12-31 was $2.83M, a 30.54% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $14.22M, a 12.79% decline from fiscal 2021.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2021 was $16.30M, a 106.20% increase from fiscal 2020.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2020 was $7.91M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2023-09-30 | $2.17M 10-Q · filed 2023-11-02 | $4.49M derived: sum of 2 quarters · filed 2023-11-02 | $6.67M 10-Q · filed 2023-11-02 | $10.20M derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | $2.32M 10-Q · filed 2023-08-10 | $4.66M 10-Q · filed 2023-08-10 | $8.03M derived: sum of 3 quarters · filed 2023-08-10 | $11.13M derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-03-31 | $2.87M 10-Q · filed 2023-05-12 | $5.70M derived: sum of 2 quarters · filed 2023-05-12 | $8.80M derived: sum of 3 quarters · filed 2023-11-02 | $12.42M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-12-31 | $2.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $5.93M derived: sum of 2 quarters · filed 2023-11-02 | $9.55M derived: sum of 3 quarters · filed 2023-11-02 | $14.22M 10-K · filed 2023-03-10 |
| 2022-09-30 | $3.10M 10-Q · filed 2023-11-02 | $6.72M derived: sum of 2 quarters · filed 2023-11-02 | $11.39M 10-Q · filed 2023-11-02 | $15.89M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $3.62M 10-Q · filed 2023-08-10 | $8.04M 10-Q · filed 2023-08-10 | $12.79M derived: sum of 3 quarters · filed 2023-08-10 | $16.21M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $5.10M 10-Q · filed 2023-05-12 | $9.17M derived: sum of 2 quarters · filed 2023-05-12 | $12.59M derived: sum of 3 quarters · filed 2023-05-12 | $17.20M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $4.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $7.49M derived: sum of 2 quarters · filed 2023-03-10 | $12.11M derived: sum of 3 quarters · filed 2023-03-10 | $16.30M 10-K · filed 2023-03-10 |
| 2021-09-30 | $3.42M 10-Q · filed 2022-11-08 | $8.03M derived: sum of 2 quarters · filed 2022-11-08 | $12.23M 10-Q · filed 2022-11-08 | $14.47M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $4.61M 10-Q · filed 2022-08-09 | $8.90M 10-Q · filed 2022-08-09 | $11.05M derived: sum of 3 quarters · filed 2022-08-09 | $13.46M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $4.28M 10-Q · filed 2022-05-04 | $6.44M derived: sum of 2 quarters · filed 2022-05-04 | $8.85M derived: sum of 3 quarters · filed 2022-05-04 | |
| 2020-12-31 | $2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $4.56M derived: sum of 2 quarters · filed 2022-03-15 | $7.91M 10-K · filed 2022-03-15 | |
| 2020-09-30 | $2.41M 10-Q · filed 2021-11-15 | $5.75M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |